Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio


Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. (NASDAQ: CBIO) on the sale of its complement asset portfolio for $60 million in cash.

This sale is part of Catalyst’s ongoing strategic process to reduce its cash burn and maximize value for its stakeholders. After the transaction, Catalyst’s product candidates consist of the coagulation related assets marzeptacog alfa (activated) (“MarzAA”), dalcinonacog alfa (“DalcA”), and CB 2679d-GT.

The Orrick team advising Catalyst Biosciences is led by Stephen Thau and includes Kayla Southworth, David Schwartz, Eric Citizen, John Narducci, Shana Solomon, Joshua Emmett, Aaron Howe, Davin Stockwell, Ashlie Smith, Christine Zgombic, Thora Johnson, Beth Goldman, Albert Vanderlaan, Danielle Mangogna and Jason Flaherty.